How do you weigh the disease control advantage of SBRT for bone metastases in Ewing sarcoma against potential late skeletal effects of high-dose-per-fraction radiation in a growing child, given limited long-term data in this population?

This question is part of our ASTRO 2026 collaboration, inspired by the Clinical Trials Session Presentation "Stereotactic Body Radiation Therapy (SBRT) and Comprehensive Metastasis-Directed Therapy for Ewing Sarcoma Patients Enrolled on AEWS1221: A Report from the Children's Oncology Group (COG)" by Dr. Nadia Laack, MD, MS

1 Answer

Mednet Member

Radiation Oncology · Harvard Medical School

Answered on

SBRT with a higher dose per fraction is likely to be similarly stunting in growth potential as conventionally fractionated high-dose radiation to 50-55.8 Gy. There is likely to be essentially no difference in growth stunting potential, and SBRT has the advantage of smaller margins added (less normal...

Join for free or sign in to see the full answer